美迈斯代理了中国的媒体和出版业公司凤凰教育对美国伊利诺伊州的Publication International Ltd.儿童图书业务收购一案。除了收购协议的架构安排和谈判，美迈斯还协助凤凰教育在中国（上海）自由贸易试验区设立了一家控股公司，并通过谈判达成了一项涉及仓储、信息技术服务、销售队伍和会计的综合性过渡协议。此项交易被《中国交易律师》杂志评为中国出版业有史以来最大的跨境交易。
一个涉及美迈斯多个代表处和业务组的团队代理中国本土的基因研究和测序公司华大基因以1.176亿美元收购Complete Genomics一案，并成功地击退了对该交易的一项恶意竞标。这是首起中国公司成功收购美国上市公司案例。在该交易宣布后不久，Illumina, Inc. 发起了对Complete Genomics的恶意竞购。美迈斯采取了反垄断和公司层面的组合防御措施最终击退了Illumina的竞购。我们还为华大完成美国和中国的监管审批程序提供了指导。我们在该交易中所做的工作获得《金融时报》2013年“美国创新律师”报告的肯定。
雄厚实力
资产收购和出售
拍卖
有争议的交易
代理金融顾问
私有化交易
合营
杠杆买断
合并
代理权争夺
资本重组
拆分和剥离
股票购买和出售
收购准备和咨询
要约收购
Apollo Global Management
O’Melveny provided diligence and documentation services to Apollo in connection with its US$875 million acquisition of Regional Care Hospital Partners from Warburg Pincus. Apollo’s investment will finance Regional Care’s plans to develop and further expand its network of hospitals in non-urban areas. Read
Avenue Capital
O’Melveny represented Avenue Capital and its managed funds as an investor in a US$350 million private placement of shares in Euronav NV, an international shipping company focused on sea-borne crude oil transportation. Read
BB&T Corporation
O’Melveny advised BB&T Corporation in connection with its agreement to acquire National Penn Bancshares, Inc. in a cash and stock transaction for total consideration valued at approximately US$1.8 billion. Read
BGI-Shenzhen
A multi-office, multi-practice O’Melveny team represented BGI Shenzhen, a China based genomic research and sequencing company, in its US$117.6 million acquisition of Complete Genomics and its successful defense of the transaction against a hostile competing bid. Read
Bristol Industries
O’Melveny represented Bristol, one of the few remaining independent manufacturers in the fastener segment of the aerospace industry, in its US$335 million acquisition by Consolidated Aerospace Manufacturing, LLC. O’Melveny counseled Bristol from the initial marketing phase through negotiation and closing of the ultimate sale. Read
Case Study: CJ ENM
O’Melveny advised CJ ENM, the leading entertainment company originated from Korea, in a definitive agreement to acquire an 80% stake of the scripted business of US-based global premium content studio, Endeavor Content, from its parent company Endeavor Group Holdings for an enterprise valuation of US$850 million. Read
Case Study: Microsemi Corporation
O'Melveny advised long-time client Microsemi on its US$10.3 billion acquisition by Microchip Technology and in the negotiated resolution of a federal securities class action challenging the merger. Read
Case Study: RSI Home Products
O’Melveny represented RSI Home Products in its definitive agreement and plan of merger with American Woodmark Corporation. Read
Chengwei Capital
O’Melveny represented Chengwei Capital as the main shareholder in Youku Tudou Inc., a leading multi-screen entertainment and media company in China, in Youku Tudou’s definitive agreement to merge an affiliate of Alibaba Group. Read
CoreLogic, Inc.
O’Melveny represented CoreLogic, a global property information, analytics, and data-enabled services provider, in the largest strategic acquisition in its history. Read
Dealertrack Technologies, Inc.
O’Melveny advised Dealertrack Technologies, Inc., a leader in software solutions and services for automotive retailers, in its US$4 billion sale to Cox Automotive, Inc. Read
Exar Corp.
O’Melveny has represented Exar, a New York Stock Exchange-listed supplier of high-performance integrated circuits and system solutions, in more than a dozen acquisitions over the years, including its acquisition of Integrated Memory Logic Limited, a fabless semiconductor company organized as a Cayman Islands exempted company and listed on the Taiwan Stock Exchange. Read
Giant Interactive
O’Melveny successfully defended Giant Interactive, one of China’s leading online game developers and operators, in a shareholder class action seeking to enjoin Giant’s proposed going-private transaction, which O’Melveny also successfully handled. Read
Giant Interactive
O’Melveny represented Giant Interactive, one of China’s leading online game developers and operators, in its US$3 billion going private transaction. Read
GoGrid
O’Melveny represented GoGrid, a cloud infrastructure service, in its acquisition by Datapipe. Read
Kabam
O’Melveny represented interactive entertainment company Kabam for more than a decade, working with the company on corporate and growth matters, including multiple venture capital and growth financings, more than a dozen strategic acquisitions, and the company’s sale to Netmarble Games for a reported US$800 million. Read
MakerBot
O’Melveny represented MakerBot, a leader in desktop 3D printing, in its acquisition by Stratasys Ltd. Read
Moelis & Co.
O’Melveny served as counsel to Moelis, financial advisor to Dentsply International in its US$5.5 billion merger with Sirona Dental Systems—a merger that creates the world’s largest maker of dental products. Read
Phoenix Education Publishing Co.
O’Melveny represented Chinese media and publishing company Phoenix Education in its acquisition of children’s book business of Illinois-based Publication International Ltd. (PIL). Read
Samsung Electronics Co. Ltd.
O’Melveny represented Samsung Electronics Co. Ltd. in its acquisition of NeuroLogica Corp., a medical imaging company. Read
Sequoia Capital and China Broadband Capital
O’Melveny represented Sequoia Capital and China Broadband Capital in forming a joint venture with LinkedIn to launch LinkedIn’s China operations, bringing the world’s largest social media platform for professionals to China. Read
Silevo
O’Melveny represented Silevo, a solar photovoltaic cell technology innovator that manufactures high-efficiency, high-performance solar modules, in its acquisition by Elon Musk’s SolarCity Corporation. Read
Skyworks Solutions, Inc.
O’Melveny acted as lead counsel to Skyworks in its US$148.5 million acquisition of a controlling interest in Panasonic Corporation’s filter technology business for smart phones and other mobile applications. Read
Warner Bros.
O’Melveny represented Warner Bros. in its acquisition of Netherlands-based TV producer Eyeworks’ businesses outside the US, comprising holdings throughout 15 territories across Europe, South America, Australia, and New Zealand. Read
WuXi PharmaTech
O’Melveny represented NYSE-listed WuXi PharmaTech (Cayman) Inc., a leading technology company serving the pharmaceutical, biotechnology, and medical device industries in the US and China, in its merger with a group of private equity investors and the company’s founders in a going-private transaction valued at US$3.3 billion. Read
Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.
